Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.
- Author:
Byung Woog KANG
1
;
Sang Kyun SOHN
;
Joon Ho MOON
;
Yee Soo CHAE
;
Jong Gwang KIM
;
Soo Jung LEE
;
Won Seog KIM
;
Je Jung LEE
;
Se Ryeon LEE
;
Keon Uk PARK
;
Ho Sup LEE
;
Won Sik LEE
;
Jong Ho WON
;
Moo Rim PARK
;
Jae Yong KWAK
;
Min Kyoung KIM
;
Hyo Jung KIM
;
Sung Yong OH
;
Hye Jin KANG
;
Cheolwon SUH
Author Information
- Publication Type:Original Article
- Keywords: Mantle cell lymphoma; Epidemiology; Trend; Survival; Chemotherapy; Rituximab
- MeSH: Bone Marrow; Cyclophosphamide; Diagnosis; Disease-Free Survival; Doxorubicin; Drug Therapy; Epidemiology; Follow-Up Studies; Humans; Incidence; Korea*; Lymphoma*; Lymphoma, Mantle-Cell*; Male; Multivariate Analysis; Prednisolone; Prognosis; Retrospective Studies; Vincristine; Rituximab
- From:Blood Research 2014;49(1):15-21
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. METHODS: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. RESULTS: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. CONCLUSION: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
